Pacira BioSciences, Inc. financial data

Symbol
PCRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
5401 West Kennedy Boulevard, Suite 890, Tampa, FL
State of incorporation
DE
Fiscal year end
December 31
Former names
Pacira Pharmaceuticals, Inc. (to 4/9/2019), PACIRA INC (to 11/5/2008), Blue Acquisition Corp (to 4/16/2007)
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 325 % -26.4%
Quick Ratio 54.5 % -43.7%
Debt-to-equity 91.1 % +3.08%
Return On Equity -12.1 % -336%
Return On Assets -6.32 % -332%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46.3M shares -0.48%
Common Stock, Shares, Outstanding 46.2M shares -0.52%
Entity Public Float 930M USD -28.5%
Common Stock, Value, Issued 47K USD +2.17%
Weighted Average Number of Shares Outstanding, Basic 46.2M shares +0.05%
Weighted Average Number of Shares Outstanding, Diluted 46.2M shares -11%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 695M USD +4.4%
Cost of Revenue 170M USD -7.71%
Research and Development Expense 81.6M USD +6.98%
Costs and Expenses 760M USD +22.3%
Operating Income (Loss) -73.4M USD -184%
Nonoperating Income (Expense) 10M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -63.1M USD -202%
Income Tax Expense (Benefit) 36.5M USD +84.6%
Net Income (Loss) Attributable to Parent -99.6M USD -337%
Earnings Per Share, Basic -2.15 USD/shares -336%
Earnings Per Share, Diluted -2.15 USD/shares -342%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 277M USD +80.5%
Accounts Receivable, after Allowance for Credit Loss, Current 113M USD +7.34%
Inventory, Net 125M USD +20.1%
Assets, Current 745M USD +46.1%
Deferred Income Tax Assets, Net 130M USD -9.77%
Property, Plant and Equipment, Net 167M USD -3.89%
Operating Lease, Right-of-Use Asset 49.2M USD -19.3%
Intangible Assets, Net (Excluding Goodwill) 426M USD -11.9%
Goodwill 0 USD -100%
Assets 1.55B USD -1.33%
Accounts Payable, Current 19.1M USD +21.9%
Employee-related Liabilities, Current 28.8M USD +32.9%
Accrued Liabilities, Current 80.1M USD +24.7%
Liabilities, Current 310M USD +218%
Operating Lease, Liability, Noncurrent 44.6M USD -18.5%
Other Liabilities, Noncurrent 16.8M USD +23.9%
Liabilities 775M USD +10.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 343K USD +38.9%
Retained Earnings (Accumulated Deficit) -206M USD -93.2%
Stockholders' Equity Attributable to Parent 778M USD -10.5%
Liabilities and Equity 1.55B USD -1.33%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 49.1M USD +157%
Net Cash Provided by (Used in) Financing Activities -2.82M USD +98.2%
Net Cash Provided by (Used in) Investing Activities -15.5M USD -123%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 47.1M shares +1.28%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 30.8M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 277M USD +80.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3.97M USD -77.5%
Deferred Tax Assets, Valuation Allowance 24.8M USD -2.76%
Deferred Tax Assets, Gross 190M USD -10.6%
Operating Lease, Liability 53.5M USD -15.8%
Depreciation 21.5M USD +17.5%
Payments to Acquire Property, Plant, and Equipment 2.84M USD -56.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -99.5M USD -334%
Lessee, Operating Lease, Liability, to be Paid 64M USD -18.5%
Property, Plant and Equipment, Gross 300M USD -2.95%
Operating Lease, Liability, Current 8.89M USD +0.98%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.3M USD -3.57%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.3M USD -5.78%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Deferred Income Tax Expense (Benefit) 3.46M USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10.5M USD -29.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.1M USD -5.79%
Deferred Tax Assets, Operating Loss Carryforwards 125M USD -5.84%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 9.37M USD +39.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10.9M USD -13.2%
Operating Lease, Payments 3.22M USD -14.5%
Additional Paid in Capital 1.01B USD +3.36%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 57.3M USD 0%
Depreciation, Depletion and Amortization 18.4M USD -6%
Deferred Tax Assets, Net of Valuation Allowance 130M USD -9.77%
Share-based Payment Arrangement, Expense 51.2M USD +6.84%
Interest Expense 14M USD -64.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%